ChestPub Date : 2026-10-03DOI: 10.1016/j.chest.2026.09.089
Ke Bi, Meng-Jun Shen, Dong Xu, Qing Tang, Yi-Xue Sun, Xiao-Fei Ye, Yi Zhang, Yang Cong, Hui-Ming Zhu, Hong-Wei Chen, Chun-Hong Tang, Yin Wang
{"title":"CEUS- versus US- and CT-guided Biopsy for Subpleural Lung Lesions: A Prospective, Multicenter Randomized Controlled Trial.","authors":"Ke Bi, Meng-Jun Shen, Dong Xu, Qing Tang, Yi-Xue Sun, Xiao-Fei Ye, Yi Zhang, Yang Cong, Hui-Ming Zhu, Hong-Wei Chen, Chun-Hong Tang, Yin Wang","doi":"10.1016/j.chest.2026.09.089","DOIUrl":"https://doi.org/10.1016/j.chest.2026.09.089","url":null,"abstract":"<p><strong>Background: </strong>Ultrasound (US)-guided percutaneous lung needle biopsy (PLNB), the guideline-recommended approach for subpleural lung lesion (SLL) diagnosis, requires comparison with CT-guided biopsy based on high-level evidence clinical studies.</p><p><strong>Research question: </strong>Is US-guided PLNB superior to CT-guided biopsy in diagnostic performance and safety, and does CEUS provide further advantages?</p><p><strong>Study design and methods: </strong>Participants undergoing PLNB for SLLs between June 2020 and November 2023 were randomized to US-, CEUS- and CT-guided biopsies. The dual primary outcomes were diagnostic yield and disease-specific diagnostic sensitivity. Diagnostic yield was defined according to the strict ATS/ACCP definition as the proportion of biopsies yielding clinically actionable diagnoses, while sensitivity referred to the proportion of patients with a confirmed disease correctly identified by biopsy. Four secondary outcomes included complication rate, CNB/FNA utilization, puncture number, and puncture time, with the overall complication rate adopted as the key safety indicator.</p><p><strong>Results: </strong>A total of 2485 participants were randomized into the US (n=828), CEUS (n=829) and CT (n=828) groups. The CEUS-guided biopsy achieved the highest diagnostic yield (CEUS: 88.8%[736/829] vs. CT: 78.9%[653/828] vs. US: 76.0%[629/828], χ<sup>2</sup>=49.046, P <0.001) , as well as the highest diagnostic sensitivity (CEUS: 86.1%[714/829] vs. CT: 74.3%[615/828] vs. US: 68.7%[569/828], χ<sup>2</sup>=72.623, P <0.001). For disease-specific analysis, CEUS yielded superior diagnostic sensitivity for malignant subtypes (CEUS: 91.8%[563/613] vs. CT: 83.2%[520/625] vs. US: 75.2%[479/637], χ<sup>2</sup>=62.259, P <0.001) and specific benign disorders (CEUS: 69.9%[151/216] vs. CT: 46.8%[95/203] vs. US: 47.1%[90/191], χ<sup>2</sup>=29.712, P <0.001). Furthermore, the CEUS group exhibited the lowest overall complication rate (CEUS: 4.6%[38/828] vs. US: 7.5%[60/802] vs. CT: 15.8%[127/805], χ<sup>2</sup>=65.322, P <0.001).</p><p><strong>Interpretation: </strong>For SLL biopsy, CEUS-guided PLNB outperforms US- and CT-guided approaches in both diagnostic performance and procedural safety. CEUS guidance notably improves disease-specific diagnostic sensitivity for malignant subtypes and specific benign pulmonary disorders, serving as an optimal technique for clinical percutaneous lung biopsy.</p><p><strong>Clinical trial registration: </strong>Chinese Clinical Trial Registry; No.: ChiCTR2100045374; URL: www.chictr.org.cn.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.8,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Sputum Cellularity and Health Services Utilization Among Patients With Asthma and COPD.","authors":"Parameswaran Nair, Kimball Zhang, Sylvia Lauks, Melanie Kjarsgaard, Sarita Thawanaphong, Jingqin Zhu, Emilie Terebessy, Teresa To","doi":"10.1016/j.chest.2026.09.091","DOIUrl":"10.1016/j.chest.2026.09.091","url":null,"abstract":"<p><strong>Background: </strong>Associations between health services utilization (HSU) and objectively measured airway inflammation in patients with severe asthma or COPD remain unclear.</p><p><strong>Research question: </strong>Is there an association between quantitative sputum cell counts and HSU (hospitalizations, physician visits, and emergency department visits) patterns in patients with asthma and COPD?</p><p><strong>Study design and methods: </strong>In this retrospective cohort study, clinical data, spirometry, and sputum cell counts (% of eosinophils and neutrophils) obtained during routine clinical assessment of patients attending a university tertiary airway disease clinic were linked to Ontario health administrative databases (2006-2019). Sputum inflammatory cell counts were treated as fixed baseline exposure variables, and negative binomial regression models using generalized estimating equations estimated rate ratios (RRs) and 95% CIs for subsequent HSU, adjusting for demographic, socioeconomic, and clinical covariates.</p><p><strong>Results: </strong>Of the 4,821 patients included, 3,714 (77%) had asthma only and 1,107 (23%) had COPD only. Among patients with asthma, sputum eosinophilia (> 3%) was associated with higher asthma-specific HSU. Compared with patients with sputum eosinophils < 3%, both the 3% to 15% and > 15% eosinophil groups had similarly increased rates of asthma-specific emergency department visits (RR, 1.92; 95% CI, 1.49-2.47; and RR, 1.88; 95% CI, 1.17-3.03). Conversely, sputum eosinophil counts were not significantly associated with HSU in COPD, whereas high sputum neutrophil counts were associated with increased all-cause hospitalizations (RR, 1.71; 95% CI, 1.11-2.64). Overall, those with higher eosinophil (> 15%) and lower neutrophil counts (< 65%) had significantly higher rates of asthma-specific and asthma-related HSU. In contrast, sputum eosinophil counts were not significantly associated with increased all-cause hospitalizations among patients with COPD.</p><p><strong>Interpretation: </strong>Our results show that sputum eosinophilia (> 3%) is associated with increased asthma-related HSU, whereas sputum eosinophils were not associated with increased HSU in COPD. These findings support the clinical relevance of airway inflammometry in asthma and highlight important differences in inflammatory phenotypes between asthma and COPD. Further studies are needed to better understand the mechanisms underlying these associations.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.8,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-03DOI: 10.1016/j.chest.2026.09.095
Linna Huang, Xu Huang, Feifei Jiao, Bing Sun, Xiaoli Han, Wancang Jiang, Weiwen Zhang, Hong Luo, Lingling Su, Ming Gu, Jun He, Longlong Jiao, Xiao Tang, Lei Jiang, Danqiong Wang, Min Yang, Xianghong Yang, Dan Li, Huaxue Wang, Xiaoliang Yuan, Hai Lin, Ziqiang Shao, Kun Lu, Bailing Yan, Yongmei Zhang, Kuan Liu, Anders Kärnell, Qingyuan Zhan
{"title":"TISA-818, an Antiinflammatory Conjugate of Montelukast-Decapeptide, in ARDS Due to Pulmonary Infection: A Phase 2 Randomized Trial Using the 2023 Global Definition.","authors":"Linna Huang, Xu Huang, Feifei Jiao, Bing Sun, Xiaoli Han, Wancang Jiang, Weiwen Zhang, Hong Luo, Lingling Su, Ming Gu, Jun He, Longlong Jiao, Xiao Tang, Lei Jiang, Danqiong Wang, Min Yang, Xianghong Yang, Dan Li, Huaxue Wang, Xiaoliang Yuan, Hai Lin, Ziqiang Shao, Kun Lu, Bailing Yan, Yongmei Zhang, Kuan Liu, Anders Kärnell, Qingyuan Zhan","doi":"10.1016/j.chest.2026.09.095","DOIUrl":"10.1016/j.chest.2026.09.095","url":null,"abstract":"<p><strong>Background: </strong>ARDS remains associated with substantial mortality. The 2023 global definition includes nonintubated patients, creating an opportunity to evaluate therapies earlier in the disease course.</p><p><strong>Research question: </strong>Is TISA-818 safe and potentially efficacious in patients with ARDS, particularly those who are nonintubated?</p><p><strong>Study design and methods: </strong>This randomized, double-anonymized, placebo-controlled, multicenter phase 2 trial was, to our knowledge, the first in China to use the 2023 global ARDS definition. Fifty-eight patients were randomized 1:1:1 to receive IV TISA-818 6 mg twice daily (BID), TISA-818 12 mg once daily (QD), or matched placebo for 14 days. The primary end point was safety. Key secondary end points included respiratory support-free days (RSFDs) through day 28, proportion of patients alive and free from respiratory support at day 14, clinical improvement rate at day 14, and length of stay through 28 days.</p><p><strong>Results: </strong>TISA-818 exhibited an acceptable safety profile with comparable rates of treatment-emergent adverse events (AEs) and no unexpected safety signals. Treatment-related AEs were mild to moderate and occurred in 5.3%, 36.8%, and 21.1% of patients in the placebo, TISA-818 6 mg BID, and TISA-818 12 mg QD groups, respectively. Day 28 mortality was 5.3%, 10.5%, and 26.3%, whereas day 60 mortality was 26.3%, 21.1%, and 31.6% for placebo, TISA-818 6 mg BID, and TISA-818 12 mg QD. No drug-related serious AEs or deaths occurred. In the prespecified nonintubated subgroup (n = 27 [9 per arm]), exploratory analyses numerically favored 6 mg BID over placebo, with more RSFDs (difference, 6 days; 95% CI, -3 to 15) and consistent numerical improvements across all secondary outcomes.</p><p><strong>Interpretation: </strong>TISA-818 was generally well tolerated. Day 28 mortality was numerically imbalanced but not sustained, likely reflecting small-sample variability; cautious interpretation is warranted. Consistent improvements across all efficacy end points, particularly with TISA-818 6 mg BID in nonintubated patients, support further investigation in adequately powered trials.</p><p><strong>Clinical trial registration: </strong>Chinadrugtrials.org number, [removed/redacted]; ClinicalTrials.gov number, [removed/redacted].</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.8,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-01DOI: 10.1016/j.chest.2026.05.010
Arun Jose
{"title":"Peering Through the \"Lens\" of Overlap in Pulmonary Vascular Diseases Due to Liver Disease: Impact of Pulmonary Arterial Hypertension Therapies on Gas Exchange in Portopulmonary Hypertension.","authors":"Arun Jose","doi":"10.1016/j.chest.2026.05.010","DOIUrl":"https://doi.org/10.1016/j.chest.2026.05.010","url":null,"abstract":"","PeriodicalId":9782,"journal":{"name":"Chest","volume":"170 4","pages":"1004-1005"},"PeriodicalIF":9.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-01Epub Date: 2026-06-03DOI: 10.1016/j.chest.2026.05.033
Hyungjin Kim, Yoosoo Chang, Soonho Yoon, Seungho Ryu
{"title":"Chest Radiograph-Derived Age Acceleration as an Early Marker of Pulmonary Dysfunction in Middle-Aged Asian Adults.","authors":"Hyungjin Kim, Yoosoo Chang, Soonho Yoon, Seungho Ryu","doi":"10.1016/j.chest.2026.05.033","DOIUrl":"10.1016/j.chest.2026.05.033","url":null,"abstract":"<p><strong>Background: </strong>Deep learning-derived chest radiographic age may capture subclinical structural changes associated with spirometric impairment.</p><p><strong>Research question: </strong>Is chest radiograph (CXR)-based accelerated aging associated with the prevalence and incidence of preserved ratio impaired spirometry (PRISm) and obstructive lung disease (OLD)?</p><p><strong>Study design and methods: </strong>This retrospective study included Korean adults who underwent CXRs and spirometry during regular health checkups between 2006 and 2019. Participants were categorized into decelerated (< -2.0 years), reference (-2.0 to 1.9 years), or accelerated (≥ 2.0 years) aging groups according to CXR-Lung-Risk scores relative to chronological age derived from baseline CXRs. Prevalent PRISm (FEV<sub>1</sub> < 80% predicted with FEV<sub>1</sub>/FVC ≥ 0.70) and OLD (FEV<sub>1</sub>/FVC < 0.70) were defined based on baseline spirometry and assessed using multivariable multinomial logistic regression. Incident PRISm and OLD were evaluated among participants with normal baseline spirometry using follow-up spirometry data through December 31, 2022, and associations were estimated using multivariable Cox proportional hazards models.</p><p><strong>Results: </strong>Among 231,278 participants (mean age, 50.7 ± 8.8 years; 55.0% male), the prevalence of PRISm and OLD was 2.2% (5,161 of 231,278) and 4.6% (10,557 of 231,278), respectively. Compared with those in the reference group, participants with accelerated aging had higher odds of prevalent PRISm (adjusted OR; 1.37; 95% CI, 1.28-1.46) and OLD (adjusted OR, 1.58; 95% CI, 1.51-1.65). In the longitudinal analysis including 104,158 participants (median follow-up, 4.3 years), accelerated aging was associated with higher risks of incident PRISm (adjusted hazard ratio, 1.37; 95% CI, 1.27-1.48) and OLD (adjusted hazard ratio, 1.28; 95% CI, 1.20-1.37). Associations were directionally consistent across subgroups defined by age, sex, smoking status, and BMI, with most subgroup analyses remaining statistically significant.</p><p><strong>Interpretation: </strong>Our results show that CXR-derived accelerated aging was associated with both current and future PRISm and OLD. These findings support a potential complementary role for routine CXRs in opportunistic identification of pulmonary dysfunction.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":"1174-1186"},"PeriodicalIF":9.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148161940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-01Epub Date: 2026-04-30DOI: 10.1016/j.chest.2026.04.027
Thomas Lacoste-Palasset, Audrey Baron, Nathan Ebstein, Antoine Beurnier, Audrey K Grech, Fabien Robert, Ly Tu, Mitja Jevnikar, Xavier Jaïs, Athénaïs Boucly, Simon Valentin, Pascal Magro, Delphine Horeau-Langlard, Benoit Aguado, Christophe Guignabert, Fabrice Bauer, David Montani, Marc Humbert, Olivier Sitbon, Laurent Savale
{"title":"Impact of Pulmonary Arterial Hypertension Therapies on Gas Exchange in Portopulmonary Hypertension.","authors":"Thomas Lacoste-Palasset, Audrey Baron, Nathan Ebstein, Antoine Beurnier, Audrey K Grech, Fabien Robert, Ly Tu, Mitja Jevnikar, Xavier Jaïs, Athénaïs Boucly, Simon Valentin, Pascal Magro, Delphine Horeau-Langlard, Benoit Aguado, Christophe Guignabert, Fabrice Bauer, David Montani, Marc Humbert, Olivier Sitbon, Laurent Savale","doi":"10.1016/j.chest.2026.04.027","DOIUrl":"10.1016/j.chest.2026.04.027","url":null,"abstract":"<p><strong>Background: </strong>Portopulmonary hypertension (PoPH) may coexist with hepatopulmonary syndrome (HPS), a condition characterized by intrapulmonary vascular dilatations (IPVDs) and hypoxemia. Although pulmonary arterial hypertension (PAH) therapies are commonly used to treat PoPH, their effects on gas exchange remain insufficiently characterized.</p><p><strong>Research question: </strong>What are the effects of PAH-specific therapies on gas exchange and the development of IPVDs in patients with PoPH?</p><p><strong>Study design and methods: </strong>A retrospective cohort of patients with PoPH was used to assess changes in the alveolar-arterial oxygen gradient (A-aDO<sub>2</sub>) following initiation of PAH therapy. A prospective cohort underwent systematic screening for IPVDs to assess their prevalence at baseline and incidence during treatment.</p><p><strong>Results: </strong>The retrospective cohort included 107 patients (70% male; mean age, 55 ± 8 years) with a baseline mean A-aDO<sub>2</sub> of 37.1 ± 13.0 mm Hg. Eighty-three patients received initial oral monotherapy and 24 received dual oral therapy. After a median follow-up of 4.5 months, A-aDO<sub>2</sub> remained stable overall (mean change, -0.92 mm Hg; 95% CI, -3.2 to 1.3; P = .42), with substantial interindividual variability. Changes in A-aDO<sub>2</sub> were not associated with variation in 6-minute walk distance or World Health Organization/New York Heart Association functional class. Baseline A-aDO<sub>2</sub> and cardiac output were independently associated with subsequent improvement in A-aDO<sub>2</sub>. Treatment-induced reductions in mean pulmonary artery pressure and increases in cardiac output correlated with greater A-aDO<sub>2</sub> improvement. In the prospective cohort (n = 28), HPS was present in 39% of patients newly diagnosed with PoPH. Baseline IPVDs did not influence A-aDO<sub>2</sub> evolution; however, 4 patients developed new IPVDs within the first year following PAH therapy initiation.</p><p><strong>Interpretation: </strong>Our results show that PAH therapy was not associated with overall deterioration in gas exchange in PoPH, despite substantial individual variability. Changes in oxygenation were linked to baseline and treatment-induced hemodynamic parameters. The development of new IPVDs in some patients warrants careful longitudinal monitoring.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":"1205-1217"},"PeriodicalIF":9.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-01DOI: 10.1016/j.chest.2026.01.037
Yijing Li, Shanshan Wei, Jialin Zhu, Weihua Gao, Xihao Hu, Xi Wang
{"title":"A 59-Year-Old Man With Fever and Dyspnea During Chemotherapy for Acute Myeloid Leukemia.","authors":"Yijing Li, Shanshan Wei, Jialin Zhu, Weihua Gao, Xihao Hu, Xi Wang","doi":"10.1016/j.chest.2026.01.037","DOIUrl":"https://doi.org/10.1016/j.chest.2026.01.037","url":null,"abstract":"<p><strong>Case presentation: </strong>A 59-year-old man with a history of acute myeloid leukemia complicated by myeloid sarcoma was receiving systemic chemotherapy.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":"170 4","pages":"e117-e122"},"PeriodicalIF":9.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-01Epub Date: 2026-05-18DOI: 10.1016/j.chest.2026.04.053
Justin M Bader, Samantha R Prince, William de Santis, Emma R Kane, Lynn Tanoue, Anna S Bader, Justin D Blasberg, Frank C Detterbeck, Gavitt A Woodard
{"title":"Natural History, Treatment, Survival, and Causes of Mortality in Patients With Subsolid and Ground-Glass Nodules.","authors":"Justin M Bader, Samantha R Prince, William de Santis, Emma R Kane, Lynn Tanoue, Anna S Bader, Justin D Blasberg, Frank C Detterbeck, Gavitt A Woodard","doi":"10.1016/j.chest.2026.04.053","DOIUrl":"10.1016/j.chest.2026.04.053","url":null,"abstract":"<p><strong>Background: </strong>Subsolid nodules (SSNs) and ground-glass opacities (GGOs) are an increasingly common clinical problem. This unique subtype of lung adenocarcinoma poses a treatment dilemma because many can be safely monitored with radiographic observation alone and require no intervention. Improved understanding of the natural history and outcomes of patients with SSNs is needed to improve clinical decision-making and treatment recommendations.</p><p><strong>Research question: </strong>What is the natural history of growth, likelihood of treatment, and most likely cause of mortality in a comprehensive cohort of patients with SSNs and GGOs identified on chest CT scan?</p><p><strong>Study design and methods: </strong>Natural language processing was used to identify all patients with SSNs on outpatient chest CT scans in 2017 (n = 17,276) in the Yale New Haven Health System. Manual chart review was performed for demographics, nodule size, growth on subsequent CT scan, treatment, pathology, and survival.</p><p><strong>Results: </strong>A cohort of 322 patients were identified with 64% (n = 207) nonsolid nodules (pure GGO) and 36% (n = 115) part-solid nodules. Over 5 years of follow-up, 81% of nonsolid nodules remained nonsolid and 19% developed a new solid component. Within 5 years, 19% (n = 60) underwent treatment, with patients with part-solid nodules being more likely to undergo treatment than those with nonsolid nodules (32% vs 11%, respectively; P < .001). Five-year overall survival was 79.8%, with 98.4% 5-year SSN-related survival. Development of a new, second primary malignancy was common in patients with SSN, who were significantly more likely to die from a secondary primary cancer than their SSN at 5 years (8.43% vs 1.54%, respectively; P < .001).</p><p><strong>Interpretation: </strong>Patients should be reassured regarding the excellent survival associated with SSNs. Our results indicate that most can be safely observed without intervention, particularly nonsolid nodules or pure GGOs. Patients with SSNs were shown to have high rates of developing multiple lung nodules and second primary lung cancer.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":"1326-1336"},"PeriodicalIF":9.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147970749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-01DOI: 10.1016/j.chest.2026.06.025
Amit Chopra, Kurt Hu, David Feller-Kopman, Marc A Judson
{"title":"Response.","authors":"Amit Chopra, Kurt Hu, David Feller-Kopman, Marc A Judson","doi":"10.1016/j.chest.2026.06.025","DOIUrl":"https://doi.org/10.1016/j.chest.2026.06.025","url":null,"abstract":"","PeriodicalId":9782,"journal":{"name":"Chest","volume":"170 4","pages":"e134-e135"},"PeriodicalIF":9.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149134458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-01Epub Date: 2026-05-14DOI: 10.1016/j.chest.2026.05.002
Yeon Wook Kim, Jeongbin Oh, Jinyong Park, Myeongju Kim, Dong Yeong Kim, Ju Gang Nam, Jong Sun Park, Jae Ho Lee, Choon-Taek Lee
{"title":"Performance and Utility of the Sybil Deep Learning Model for Lung Cancer Risk Prediction in Asian High- and Low-Risk Populations.","authors":"Yeon Wook Kim, Jeongbin Oh, Jinyong Park, Myeongju Kim, Dong Yeong Kim, Ju Gang Nam, Jong Sun Park, Jae Ho Lee, Choon-Taek Lee","doi":"10.1016/j.chest.2026.05.002","DOIUrl":"10.1016/j.chest.2026.05.002","url":null,"abstract":"<p><strong>Background: </strong>Sybil is a deep learning model designed to predict future lung cancer risk based on a single low-dose chest CT (LDCT) scan, facilitating a precision-based approach to lung cancer screening (LCS).</p><p><strong>Research question: </strong>What are the performance and utility of Sybil in a pragmatic Asian LCS cohort?</p><p><strong>Study design and methods: </strong>We analyzed 21,087 individuals 50 to 80 years of age who underwent LDCT screening between January 2009 and December 2021. Baseline LDCT scans were evaluated using Sybil to calculate the risk of lung cancer diagnosis within 1 to 6 years. Model performance was assessed with the area under the receiver operating characteristic curve (AUROC). Stratified analyses were conducted for individuals with ≥ 20 pack-years (PYs) of smoking history (n = 4,611), individuals who ever smoked with < 20 or unknown PYs (n = 5,378), and individuals who have never smoked (INS) (n = 11,098).</p><p><strong>Results: </strong>Among 21,087 participants, subsolid nodules were more common in INS (9.3%) than in those with ≥ 20 PYs (7.1%) or < 20/unknown PYs (6.7%) (P < .001). A total of 257 participants were diagnosed with lung cancer within 6 years. Sybil achieved AUROCs of 0.86 (95% CI, 0.82-0.89) for 1-year invasive lung cancer predictions and 0.74 (95% CI, 0.70-0.77) for 6-year invasive lung cancer predictions. For INS, AUROCs were 0.86 (95% CI, 0.81-0.91) for 1-year predictions and 0.79 (95% CI, 0.74-0.84) for 6-year predictions. Sybil's short-term performance declined in individuals with LDCT findings of granulomatous sequelae, but long-term performance was maintained. Reduced performance was also observed in individuals with subsolid nodules and those without a detected baseline nodule. Five-year overall survival among lung cancer cases was 92.7% in INS, 75.9% for < 20/unknown PYs, and 68.6% in ≥ 20 PYs (P < .001).</p><p><strong>Interpretation: </strong>Our results show that Sybil demonstrated robust performance in predicting future lung cancer in an Asian screening cohort composed of individuals with diverse risk profiles. The findings highlight the potential to develop personalized LCS strategies using Sybil to address region-specific needs.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":"1311-1325"},"PeriodicalIF":9.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147947794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}